Amgen’s Clever $2.7 Billion Investment in Chinese Biotech Firm BeiGene

California-based biotech firm, Amgen announced that it's investing $2.7 billion in BeiGene taking a 20.5% stake in the Chinese company. Amgen, which has yet to establish a strong oncology presence in China, compared to its multinational rivals including Roche, Novartis, and AstraZeneca, now looks to BioGene...